Back to Journals » International Journal of Women's Health » Volume 11

Triple-negative breast cancer: current perspective on the evolving therapeutic landscape

Authors Mehanna J, Haddad FGH, Eid R, Lambertini M, Kourie HR

Received 30 March 2019

Accepted for publication 9 July 2019

Published 31 July 2019 Volume 2019:11 Pages 431—437


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Elie Al-Chaer

Joe Mehanna,1 Fady GH Haddad,1 Roland Eid,1 Matteo Lambertini,2,3 Hampig Raphael Kourie1

1Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon; 2Department of Medical Oncology, U.O.C. Clinica Di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 3Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy

Abstract: Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the current standard of care in the treatment of TNBC in the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing phase III clinical trials evaluating different associations between the 3 pillars of anticancer treatment: chemotherapy, targeted therapy and immunotherapy.

Keywords: breast cancer, triple-negative, immunotherapy, PARP inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]